vs
MESA LABORATORIES INC（MLAB）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
RESOURCES CONNECTION, INC.的季度营收约是MESA LABORATORIES INC的1.8倍（$117.7M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs -10.8%，领先16.3%），MESA LABORATORIES INC同比增速更快（3.6% vs -19.2%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $15.6M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -11.8%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
MLAB vs RGP — 直观对比
营收规模更大
RGP
是对方的1.8倍
$65.1M
营收增速更快
MLAB
高出22.8%
-19.2%
净利率更高
MLAB
高出16.3%
-10.8%
自由现金流更多
MLAB
多$2.5M
$15.6M
两年增速更快
MLAB
近两年复合增速
-11.8%
损益表 — Q3 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $117.7M |
| 净利润 | $3.6M | $-12.7M |
| 毛利率 | 64.2% | 37.1% |
| 营业利润率 | 12.2% | -10.3% |
| 净利率 | 5.6% | -10.8% |
| 营收同比 | 3.6% | -19.2% |
| 净利润同比 | 316.6% | 81.6% |
| 每股收益（稀释后） | $0.65 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABRGP
| Q4 25 | $65.1M | $117.7M | ||
| Q3 25 | $60.7M | $120.2M | ||
| Q2 25 | $59.5M | $139.3M | ||
| Q1 25 | $62.1M | $129.4M | ||
| Q4 24 | $62.8M | $145.6M | ||
| Q3 24 | $57.8M | $136.9M | ||
| Q2 24 | $58.2M | $148.2M | ||
| Q1 24 | $58.9M | $151.3M |
净利润MLABRGP
| Q4 25 | $3.6M | $-12.7M | ||
| Q3 25 | $2.5M | $-2.4M | ||
| Q2 25 | $4.7M | $-73.3M | ||
| Q1 25 | $-7.1M | $-44.1M | ||
| Q4 24 | $-1.7M | $-68.7M | ||
| Q3 24 | $3.4M | $-5.7M | ||
| Q2 24 | $3.4M | $10.5M | ||
| Q1 24 | $-254.6M | $2.5M |
毛利率MLABRGP
| Q4 25 | 64.2% | 37.1% | ||
| Q3 25 | 61.5% | 39.5% | ||
| Q2 25 | 62.0% | 40.2% | ||
| Q1 25 | 61.8% | 35.1% | ||
| Q4 24 | 63.3% | 38.5% | ||
| Q3 24 | 61.3% | 36.5% | ||
| Q2 24 | 64.0% | 40.2% | ||
| Q1 24 | 62.1% | 37.0% |
营业利润率MLABRGP
| Q4 25 | 12.2% | -10.3% | ||
| Q3 25 | 7.8% | -1.7% | ||
| Q2 25 | 5.1% | -47.0% | ||
| Q1 25 | 2.4% | -38.4% | ||
| Q4 24 | 9.2% | -52.7% | ||
| Q3 24 | 6.1% | -3.5% | ||
| Q2 24 | 9.6% | 7.6% | ||
| Q1 24 | -460.6% | 2.8% |
净利率MLABRGP
| Q4 25 | 5.6% | -10.8% | ||
| Q3 25 | 4.1% | -2.0% | ||
| Q2 25 | 8.0% | -52.6% | ||
| Q1 25 | -11.4% | -34.0% | ||
| Q4 24 | -2.7% | -47.2% | ||
| Q3 24 | 5.9% | -4.2% | ||
| Q2 24 | 5.8% | 7.1% | ||
| Q1 24 | -432.2% | 1.7% |
每股收益（稀释后）MLABRGP
| Q4 25 | $0.65 | $-0.38 | ||
| Q3 25 | $0.45 | $-0.07 | ||
| Q2 25 | $0.85 | $-2.21 | ||
| Q1 25 | $-1.30 | $-1.34 | ||
| Q4 24 | $-0.31 | $-2.08 | ||
| Q3 24 | $0.63 | $-0.17 | ||
| Q2 24 | $0.62 | $0.31 | ||
| Q1 24 | $-47.26 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $89.8M |
| 总债务越低越好 | $68.4M | — |
| 股东权益账面价值 | $186.7M | $194.6M |
| 总资产 | $434.8M | $289.3M |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资MLABRGP
| Q4 25 | $29.0M | $89.8M | ||
| Q3 25 | $20.4M | $77.5M | ||
| Q2 25 | $21.3M | $86.1M | ||
| Q1 25 | $27.3M | $72.5M | ||
| Q4 24 | $27.3M | $78.2M | ||
| Q3 24 | $24.3M | $89.6M | ||
| Q2 24 | $28.5M | $108.9M | ||
| Q1 24 | $28.2M | $113.8M |
总债务MLABRGP
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABRGP
| Q4 25 | $186.7M | $194.6M | ||
| Q3 25 | $178.5M | $206.4M | ||
| Q2 25 | $172.5M | $207.1M | ||
| Q1 25 | $159.8M | $277.8M | ||
| Q4 24 | $155.2M | $325.7M | ||
| Q3 24 | $161.5M | $407.2M | ||
| Q2 24 | $150.7M | $418.8M | ||
| Q1 24 | $145.4M | $414.9M |
总资产MLABRGP
| Q4 25 | $434.8M | $289.3M | ||
| Q3 25 | $430.4M | $287.2M | ||
| Q2 25 | $435.7M | $304.7M | ||
| Q1 25 | $433.3M | $375.6M | ||
| Q4 24 | $433.3M | $424.9M | ||
| Q3 24 | $454.1M | $512.9M | ||
| Q2 24 | $440.4M | $510.9M | ||
| Q1 24 | $446.8M | $523.2M |
负债/权益比MLABRGP
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $15.6M |
| 自由现金流率自由现金流/营收 | 27.7% | 13.2% |
| 资本支出强度资本支出/营收 | 1.1% | 0.3% |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | $24.3M |
8季度趋势，按日历期对齐
经营现金流MLABRGP
| Q4 25 | $18.8M | $15.9M | ||
| Q3 25 | $8.2M | $-7.8M | ||
| Q2 25 | $1.9M | $16.8M | ||
| Q1 25 | $12.7M | $659.0K | ||
| Q4 24 | $18.1M | $1.8M | ||
| Q3 24 | $5.3M | $-309.0K | ||
| Q2 24 | $10.7M | $3.2M | ||
| Q1 24 | $12.9M | $20.5M |
自由现金流MLABRGP
| Q4 25 | $18.0M | $15.6M | ||
| Q3 25 | $7.1M | $-8.0M | ||
| Q2 25 | $884.0K | $16.5M | ||
| Q1 25 | $11.9M | $238.0K | ||
| Q4 24 | $17.3M | $61.0K | ||
| Q3 24 | $3.5M | $-575.0K | ||
| Q2 24 | $9.9M | $3.0M | ||
| Q1 24 | $12.3M | $20.4M |
自由现金流率MLABRGP
| Q4 25 | 27.7% | 13.2% | ||
| Q3 25 | 11.7% | -6.6% | ||
| Q2 25 | 1.5% | 11.8% | ||
| Q1 25 | 19.2% | 0.2% | ||
| Q4 24 | 27.6% | 0.0% | ||
| Q3 24 | 6.0% | -0.4% | ||
| Q2 24 | 16.9% | 2.1% | ||
| Q1 24 | 21.0% | 13.5% |
资本支出强度MLABRGP
| Q4 25 | 1.1% | 0.3% | ||
| Q3 25 | 1.8% | 0.1% | ||
| Q2 25 | 1.7% | 0.2% | ||
| Q1 25 | 1.2% | 0.3% | ||
| Q4 24 | 1.3% | 1.2% | ||
| Q3 24 | 3.1% | 0.2% | ||
| Q2 24 | 1.5% | 0.1% | ||
| Q1 24 | 0.9% | 0.1% |
现金转化率MLABRGP
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | 0.30× | ||
| Q1 24 | — | 8.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
